HFM1 and NEIL1 may serve as potential prognostic biomarkers, but the carcinogenesis of these genes in ESCC needs to be further validated in vivo and in vitro, as does their role in the immune response. This evidence concerns the gene HFM1 and esophageal squamous cell carcinoma.